About Cygnus Biosciences

Company

About Cygnus Biosciences

Who We Are

Cygnus Biosciences is a global innovator in sequencing technologies, dedicated to developing advanced sequencing platforms and proprietary core technologies for Sequencing the Future. With scalable sequencing solutions ranging from Gb to Tb, Cygnus serves applications across life science research, clinical diagnostics, pharmaceutical R&D, agriculture genomics, public health, and precision medicine.

Cygnus has established an integrated sequencing ecosystem spanning instruments, consumables, and automated bioinformatics tools, with independent development and manufacturing of core technologies. Its platforms support research, clinical testing, population genomics, and biobank projects, with key technological advances published in leading scientific journals including Nature Biotechnology, Nature Biomedical Engineering, and National Science Review.

Who We Are

Our Vision

Sequencing the Future

Shaping the future of life sciences through innovative sequencing technologies.

Our Values

Stay Curious

Explore new possibilities and keep pushing the boundaries of science and technology.

Think Ahead

Anticipate change, think strategically, and prepare for what comes next.

Keep Evolving

Learn continuously, embrace change, and improve ourselves and what we do.

Stay Ahead

Stay alert to challenges and opportunities, act early, and strive to lead the way.

Milestones

LumoSeq Technology published in Nature Methods

Cygnus founded

Series A financing completed

Beijing R&D center and GMP manufacturing facility completed

Core sequencing PCT patents granted globally (including US)

Guangzhou branch launched

Series B and Series C financing completed

GS100 officially launched with scaled production capabilities

Obtained EU CE certification, NMPA approval, and ISO 13485 certification

Expanded research and clinical applications

Shenzhen branch launched

Completed Series C+ financing

GS200 launched with EU CE-IVDR certification

GP1000 and GP1000X launched for high-throughput sequencing applications

Series D financing completed

2010–2014 Innovation Foundation

2015 Company Founded

2016–2020 Platform Development

2021–2024 Commercial Growth

2025–Present Global Expansion

Corporate Honors & Qualifications

Awards

  • 2021 Rising Star Enterprise of "Innovation China"
  • Pioneer Team for Scientific and Technological Research
  • Top 10 Most Promising Biotech Enterprises on 2022 China Biomedical Industry List
  • 2023 Hurun Global Cheetah Enterprise
  • 2023 Deloitte China Healthcare Rising Star

Qualifications

  • Listed in the 3rd Batch of Beijing Major Technical Equipment (2024)
  • Certified as Beijing New Technology & New Product (Service)
  • Zhongguancun Frontier Technology Enterprise
  • Academician & Expert Workstation
  • Patent Examiner Practice Base (Zhongguancun), National Intellectual Property Administration
  • Beijing Specialized, Refined, Distinctive & Innovative SME (Small and Medium-sized Enterprises)
  • Zhongguancun High-tech Enterprise
  • National High-tech Enterprise
  • ISO13485 Certification